Perceptive Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Perceptive Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$350M	Buy	1,531,421 +450,000	+42%	+$101M	6.84%	3
2025 Q4	$231M	Sell	1,081,421 -7,080	-0.7%	-$1.46M	4.11%	4
2025 Q3	$216M	Buy	1,088,501 +124,615	+13%	+$23.2M	6.25%	2
2025 Q2	$166M	Buy	+963,886	New	+$157M	6.17%	2
2024 Q1	–	Sell	-132,176	Closed	-$16.6M	–	114
2023 Q4	$16.6M	Buy	+132,176	New	+$13.2M	0.37%	54
2019 Q3	–	Sell	-473,475	Closed	-$54.5M	–	110
2019 Q2	$54.5M	Sell	473,475 -639,853	-57%	-$76.6M	1.25%	19
2019 Q1	$131M	Buy	1,113,328 +60,681	+6%	+$5.31M	3.7%	6
2018 Q4	$63M	Sell	1,052,647 -20,000	-2%	-$1.26M	2.4%	10
2018 Q3	$76M	Hold	1,072,647	–	–	2.03%	10
2018 Q2	$71.4M	Buy	1,072,647 +90,000	+9%	+$5.92M	1.87%	12
2018 Q1	$64.3M	Buy	+982,647	New	+$55.2M	1.8%	15
2015 Q3	–	Sell	-10,000	Closed	-$176K	–	159
2015 Q2	$176K	Hold	10,000	–	–	0.01%	166
2015 Q1	$174K	Buy	+10,000	New	+$182K	0.01%	150

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors's ASND Position: Q1 2026 in Review

Perceptive Advisors increased its Ascendis Pharma A/S (ASND) stake by 42% in Q1 2026, buying an estimated $101M and bringing the position to 1,531,421 shares worth $350M. The position accounts for 6.84% of the portfolio, ranked #3.

Perceptive Advisors first reported a position in ASND in Q1 2015 and has held it in 13 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Perceptive Advisors held 1,531,421 shares of Ascendis Pharma A/S worth $350M as of Q1 2026.
Perceptive Advisors bought 450,000 Ascendis Pharma A/S shares in Q1 2026, an estimated $101M.
Ascendis Pharma A/S made up 6.84% of Perceptive Advisors's portfolio in Q1 2026, its #3 holding.
Perceptive Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 13 quarters since.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.